Zaluvida Ventures

What Zaluvida Ventures does

Zaluvida Ventures is a family-owned venture builder platform founded in 2005 by Thomas Hafner and Carin Beumer, focused on building and scaling companies that advance human and planetary health. The firm evolved from a direct-operating life sciences group — which launched world-first products including Liposinol (the first Class II Medical Device for substance-based oral obesity treatment, 2006) and PhaseLite — into a strategic investment and venture-building vehicle following a 2018 restructuring. Its current portfolio comprises six active ventures spanning consumer health (InQpharm), health innovation R&D (InQLABS), advanced wound care (Onya Therapeutics, leveraging proprietary Active Edge Technology), rare skin disorders (Mariposa Therapeutics), sustainable agriculture and antimicrobial resistance (Avanterra), and AI-powered autonomous venture building (OpenServ, powered by a proprietary SERV reasoning framework). Legacy ventures such as Mootral (livestock methane reduction, CowCredits carbon credits) and Analyze & Realize (consumer health CRO) represent prior exits, while technology acquisitions including Neem Biotech's patented allicin/ajoene platform (2011) and LiveExtract/Grazexin (2016) underpin the group's antibiotic-alternative and animal-health capabilities.

The firm's business model combines venture capital-style capital allocation with operator-led support: Zaluvida provides governance, regulatory affairs expertise, IP strategy, and commercialization networks to portfolio companies targeting founders whose missions align with human and planetary health. Revenue is generated through a mix of consumer health product sales (15B+ doses delivered historically across 50+ countries, surpassing 1B tablets annually by 2014), licensing and royalty arrangements, strategic transactions and exits (most notably the €141M sale of the European obesity and allergy business to Omega Pharma in 2014), and emerging carbon-credit marketplace revenue via Mootral's CowCredits. The group is registered across the UK (Hitchin), Singapore, Malaysia (Kuala Lumpur), and Switzerland (Rolle), operates with 51–100 employees post-restructuring, and has never raised external funding — bootstrapping its two-decade track record on internal cash flow and reinvested exit proceeds.

Regulatory milestones — including the 2006 Liposinol Class II Medical Device certification, 2008 PhaseLite certification, and 2016 FDA orphan drug designation for a cystic fibrosis treatment — alongside proprietary technology platforms (AET, SERV, allicin/ajoene, LiveExtract) constitute the core intangible assets supporting the platform. Zaluvida distinguishes itself through patient, purpose-aligned capital, deep operational involvement across regulatory, IP, and commercialization stages, and a global network of partners and distributors cultivated over two decades of cross-continent operations, including humanitarian engagement as the main financial constituent of HealthNet TPO from 2015 to 2023 (serving 45M+ people in crisis zones).

Name

Zaluvida Ventures

Legal name

Zaluvida Ventures Ltd

Website

https://zaluvida.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

Zaluvida Ventures is a family-owned venture builder founded in 2005 that builds and scales life-sciences companies advancing human and planetary health, operating six active ventures across consumer health, wound care, rare disease, sustainable agriculture, and AI-powered autonomous venture building.

Ownership category

akta.pro rank

Product category

Venture Building / Life Sciences Investment

NAICS

Other Investment Pools and Funds (5259), Other Financial Vehicles (52599)

SIC

Investment Advice (6282)

akta.pro primary industry

Strategic / Balance-Sheet CVC (On-balance-sheet investing) (FSANAHAA)

akta.pro secondary industries

Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF), Corporate M&A / Venture Build-to-Buy Programs (Acqui-hire, option-to-acquire) (FSANAHAG)

Keywords

• Venture capital services
• Life sciences investment
• Consumer health products
• Biopharmaceutical development
• Sustainable agriculture solutions

Headquarters

HQ city

Rolle

HQ country

Switzerland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Venture Building and Strategic Investment: Zaluvida operates as a venture builder and strategic partner, providing capital, governance, operational expertise, and strategic counsel to portfolio companies. Revenue generated through successful exits, portfolio company growth, and strategic transactions.
2. Consumer Health Products: Through InQpharm and portfolio companies, generates revenue from clinically proven, IP-protected consumer health products across obesity, gastrointestinal health, allergy, and general health areas. Products sold in 50+ countries with over 15 billion doses delivered.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

Zaluvida Ventures is a family-owned venture builder platform that funds, builds, and scales purpose-driven companies at the intersection of human and planetary health. Through its six active portfolio ventures, Zaluvida develops and commercializes proprietary consumer health products, pharmaceutical-grade wound and skin treatments, sustainable agriculture solutions, and an AI-powered platform for autonomous ventures.

Product overview

Zaluvida Ventures is a venture builder platform focused on human and planetary health. The portfolio consists of six active ventures across health and sustainability: Onya Therapeutics (advanced wound care via Active Edge Technology), Mariposa Therapeutics (treatments for keratin disorders), Avanterra (sustainable agriculture), InQpharm (consumer health across obesity, GI, allergy), InQLABS (R&D accelerator), and OpenServ (AI-powered platform for autonomous ventures). The platform also includes legacy/exit ventures (Mootral, Analyze & Realize, NX Ventures, Prosanita Healthcare) and historical products (Liposinol, Prevalin, Grazexin). Zaluvida provides strategic investment, mentorship, and operational support rather than a unified software product.

Differentiator

Problem solved

Functional benefit

Products and services

• OpenServ AI-powered platform enabling anyone to build, launch, and run autonomous ventures using AI agents with a proprietary SERV reasoning framework and app launchpad.
• InQLABS Consumer health R&D accelerator driving development of next-generation compounds, formulations, and delivery systems across human health from ideation through regulatory approval and commercialisation.
• InQpharm Global consumer health company delivering clinically proven, IP-protected solutions across obesity, gastrointestinal health, allergy, and general health activation with treatments reaching patients in more than 50 countries.
• Avanterra Sustainable agriculture company reducing climate impact and addressing antimicrobial resistance driven by antibiotic overuse in animal protein production.
• Mariposa Therapeutics Biopharmaceutical venture developing first-in-class treatments for keratin disorders, targeting the underlying biology of keratinization for rare, debilitating skin conditions with no approved therapies.
• Onya Therapeutics Biopharmaceutical venture pioneering the shift from wound care to wound cure through proprietary Active Edge Technology (AET) and lead candidate OTX-PP01, developing pharmaceutical-grade wound treatments that activate the body's own healing response for chronic wounds.

Quantifiable outcome

• 15 billion+ doses of accessible self-care delivered globally
• +6 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• LiveExtract Technology LicensorscoreTechnology or Integration · 1 January 2016Acquired LiveExtract technology (Grazexin) in 2016 - a highly effective natural alternative to antibiotics for production animals. This technology was integrated into Mootral's product development.
• MootralcoreStrategic or Co-development Partner · 1 January 2016Mootral was founded and launched at COP 22 in Marrakech in 2016 as the first viable solution to reduce methane emissions from ruminants. Mootral pioneered the world's first carbon credits from methane mitigation in livestock (CowCredits), creating an entirely new category from scratch. This represents Zaluvida's venture building at work.
• Biofortis GroupminorStrategic or Co-development Partner · 1 January 2016Analyze & Realize (A&R), a leading CRO and consultancy in consumer health that pioneered regulatory and clinical research services for natural health products across Europe, became part of the Biofortis Group as part of Zaluvida's legacy and exit strategy.
• HealthNet TPOcoreStrategic or Co-development Partner · 1 January 2015From 2015 to 2023, Zaluvida was the main financial constituent of HealthNet TPO, a global NGO serving tens of millions in crisis zones across Afghanistan, South Sudan, Burundi, Cambodia, and other regions. Co-founder Carin Beumer served as Chairman of the Board, providing strategic governance and operational expertise. The organization served more than 45 million people in crisis zones.
• Neem BiotechcoreTechnology or Integration · 1 January 2011Acquired exclusive rights to Neem Biotech's patented allicin/ajoene technology in 2011 - a visionary decision for Zaluvida's future. This antibiotic alternative technology became a cornerstone of Zaluvida's innovation portfolio. Neem Biotech's state-of-the-art facility opened in 2015, officiated by the Welsh Minister.
• Omega Pharma NVcoreChannel Partner/ Reseller/ Distributor · 1 January 2010Strategic alliance with Omega Pharma NV for commercialization across Greater Europe in 2010. Zaluvida's gastrointestinal product range achieved regulatory approval and was commercialized through this partnership. In 2014, Zaluvida sold its European obesity and allergy business to Omega Pharma for €141 million net value.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Flagship Pioneering: Flagship Pioneering is a life sciences-focused venture builder that creates and funds biotechnology companies from inception, mirroring Zaluvida's model of building, scaling, and exiting purpose-driven science ventures. Both platforms incubate companies internally across health and sustainability with multi-year capital commitment.
• IndieBio (SOSV): IndieBio is a life sciences accelerator and venture builder operating multiple cohorts of biotech startups with deep operational support, directly comparable to Zaluvida's venture-building model across health, agriculture, and food systems.

Broad incumbents

• Leaps by Bayer: Leaps by Bayer is Bayer's corporate venture arm investing in life sciences and agriculture breakthroughs, comparable to Zaluvida's life sciences focus but with substantially larger capital and corporate backing. Both target human and planetary health with breakthrough science platforms.
• Novartis Venture Fund: Novartis Venture Fund is the corporate venture arm of a major pharmaceutical company, investing across therapeutic areas where Zaluvida's portfolio (wound care, rare disease) competes for similar breakthrough science opportunities.

Emerging players

• Petri.bio: Petri is an early-stage biotech venture studio building new therapeutic companies from internal science, directly comparable to Zaluvida's Mariposa Therapeutics and Onya Therapeutics incubation model in life sciences.
• Builders Vision: Builders Vision is an impact-focused venture builder backing companies addressing human and planetary health challenges, with comparable mission alignment to Zaluvida's purpose-driven venture portfolio.
• Recursion Pharmaceuticals: Recursion is an AI-driven biotech platform combining proprietary technology with venture-style pipeline development, comparable in approach to OpenServ's AI-powered autonomous venture platform within Zaluvida's portfolio.
• Apollo Health Ventures: Apollo Health Ventures is a venture capital firm focused on aging and healthspan, overlapping with Zaluvida's chronic disease and preventive health thesis through portfolio companies like InQpharm.

Others

• Lux Capital: Lux Capital is a science and technology venture capital firm investing in frontier health, agriculture, and climate solutions, overlapping thematically with Zaluvida's portfolio categories but operating as a fund rather than a venture builder.
• Norrsken Foundation: Norrsken Foundation operates an impact venture fund supporting entrepreneurs addressing global health and sustainability challenges, sharing Zaluvida's mission alignment but structured as a foundation-backed fund rather than a venture builder.

Market position

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/zalufoundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zaluvida Ventures